drugset / Trial / NCT06784557

Effect of Ezetimibe on Gut Microbiota

NCT06784557

Phase 4 Recruiting 110 enrolled Yonsei University
RandomizedParallel-groupOpen-labelTreatment

Summary

Ezetimibe exerts its primary effects by inhibiting intestinal cholesterol absorption through the NPC1L1 protein. Beyond this, its impact on gut microbiota remains an area of interest. Gut microbiota has been implicated in cholesterol metabolism and CVD pathogenesis through metabolic and non-metabolic pathways. Modulating gut microbiota has been explored as a potential strategy to prevent CVDs. Despite its intestinal mechanism, the influence of ezetimibe on gut microbiota composition has not been thoroughly investigated. Future studies are needed to elucidate its potential interactions with gut microbial communities and their implications for cholesterol metabolism and cardiovascular health.

Timeline

Start
2024-02-28
Primary completion
2025-07-01
Completion
2025-10-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Atorvastatin Small molecule 20 mg Oral
Comparator Atorvastatin Small molecule 40 mg Oral
Subject Ezetimibe Unknown 10 mg Oral